The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer’s disease

Kalinin, Sergey; Polak, Paul E.; Lin, Shao Xia; Sakharkar, Amul J.; Pandey, Subhash C.; Feinstein, Douglas L.

doi:10.1016/j.neurobiolaging.2011.04.012

Cited by 116Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsDementia and Cognitive Impairment Research

The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer’s disease

Open access

Kalinin, Sergey, Polak, Paul E., Lin, Shao Xia, Sakharkar, Amul J., Pandey, Subhash C., Feinstein, Douglas L.·2012·Neurobiology of Aging

DOI 10.1016/j.neurobiolaging.2011.04.012PMC PMC3646366

Open this paper in CoChat — free account

Abstract

Damage to noradrenergic neurons in the locus coeruleus (LC) is a hallmark of Alzheimer's disease (AD) and may contribute to disease progression. In 5xFAD transgenic mice, which accumulate amyloid burden at early ages, the LC undergoes stress as evidenced by increased astrocyte activation, neuronal hypertrophy, reduced levels of LC-enriched messenger RNAs (mRNAs), and increased inflammatory gene expression. Central nervous system (CNS) noradrenaline (NA) levels in 5-month-old male 5xFAD mice were increased using the NA precursor L-threo-3,4-dihydroxyphenylserine (L-DOPS). After 1 month, L-DOPS treatment improved learning in the Morris water maze test compared with vehicle-treated mice. L-DOPS increased CNS NA levels, and average latency times in the water maze test were inversely correlated to NA levels. L-DOPS reduced astrocyte activation and Thioflavin-S staining; increased mRNA levels of neprilysin and insulin degrading enzyme, and of several neurotrophins; and increased brain-derived neurotrophic factor protein levels. These data demonstrate the presence of LC stress in a robust mouse model of AD, and suggest that raising CNS NA levels could provide benefit in AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.neurobiolaging.2011.04.012

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A reduced plaque burden has been shown to be accompanied by a reduced glial activation.
“a reduced plaque burden has been shown to be accompanied by a reduced glial activation [6], [60].”
From Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease (2014) · cites this paper as [60]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859 · see citing works
Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 3× · see citing works
“In these studies we used 5xFAD mice (Oakley et al., 2006), which harbor 3 mutations in the amyloid precursor protein (APP) gene and 2 in the presenilin-1 (PS1) gene; they accumulate soluble Aβ1–42 and develop plaques by 4 to 5 weeks age, and show frank neuronal damage including intraneuronal accumulation of Aβ1–42 and…”
BackgroundMethod
The locus coeruleus and noradrenergic modulation of cognition
Sara, S. J. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2573 · Cited by 1,848 · see citing works
The essential role of hippocampal CA1 NMDA receptor-dependent synaptic plasticity in spatial memory.
Tsien, J. Z., Huerta, P. T., & Tonegawa, S. (1996) · Cell · doi:10.1016/s0092-8674(00)81827-9 · Cited by 1,782 · cited 1× · see citing works
“Our findings that L-DOPS also reduced amyloid burden and inflammation in the hippocampus is consistent with the fact that learning in the Morris water maze test is considered to be dependent on hippocampal function (Tsien et al., 1996).”
Result
TrkB signalling pathways in LTP and learning
Minichiello, L. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2738 · Cited by 1,055 · see citing works
Neuronal Loss Is Greater in the Locus Coeruleus Than Nucleus Basalis and Substantia Nigra in Alzheimer and Parkinson Diseases
Zarow, C., Lyness, S. A., Mortimer, J. A., & Chui, H. C. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.337 · Cited by 1,003 · see citing works
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782 · see citing works
Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease
Peng, S., Wuu, J., Mufson, E. J., & Fahnestock, M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03135.x · Cited by 691 · see citing works
Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine
Heneka, M. T., Nadrigny, F., Regen, T., Martinez-Hernandez, A., Dumitrescu‐Ozimek, L., Terwel, D., Jardanhazi‐Kurutz, D., Walter, J., Kirchhoff, F., Hanisch, U., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909586107 · Cited by 517 · see citing works
Disease‐specific patterns of locus coeruleus cell loss
German, D. C., Manaye, K. F., White, C. L., Woodward, D. J., McIntire, D. D., Smith, W. K., Kalaria, R. N., & Mann, D. M. A. (1992) · Annals of Neurology · doi:10.1002/ana.410320510 · Cited by 512 · see citing works
Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans
Samuels, E., & Szabadi, E. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777193 · Cited by 454 · see citing works
Changes in the Brain Catecholamines in Patients with Dementia of Alzheimer Type
Adolfsson, R., Gottfries, C. G., Roos, B. E., & Winblad, B. G. (1979) · The British Journal of Psychiatry · doi:10.1192/bjp.135.3.216 · Cited by 449 · see citing works
Noradrenergic mechanisms in neurodegenerative diseases: a theory
Marien, M. R., Colpaert, F. C., & Rosenquist, A. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.02.002 · Cited by 411 · see citing works
Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice
Heneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., Sastre, M., Galldiks, N., Zimmer, A., Hoehn, M., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4236-05.2006 · Cited by 305 · see citing works
Temporal memory deficits in Alzheimer’s mouse models: Rescue by genetic deletion of BACE1
Ohno, M., Chang, L., Tseng, W., Oakley, H., Citron, M., Klein, W. L., Vassar, R., & Disterhoft, J. F. (2006) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04551.x · Cited by 298 · see citing works
Noradrenergic Depletion Potentiates β-Amyloid-Induced Cortical Inflammation: Implications for Alzheimer's Disease
Heneka, M. T., Galea, E., Gavriluyk, V., Dumitrescu‐Ozimek, L., Daeschner, J., O’Banion, M. K., Weinberg, G. L., Klockgether, T., & Feinstein, D. L. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02434.2002 · Cited by 261 · see citing works
Compensatory Changes in the Noradrenergic Nervous System in the Locus Ceruleus and Hippocampus of Postmortem Subjects with Alzheimer's Disease and Dementia with Lewy Bodies
Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R., & Raskind, M. A. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.4265-05.2006 · Cited by 249 · see citing works
Neurotrophin-3 prevents the death of adult central noradrenergic neurons in vivo
Arenas, E., & Persson, H. (1994) · Nature · doi:10.1038/367368a0 · Cited by 209 · see citing works
Prazosin for the Treatment of Behavioral Symptoms in Patients With Alzheimer Disease With Agitation and Aggression
Wang, L. Y., Shofer, J. B., Rohde, K., Hart, K. L., Hoff, D. J., McFall, Y. H., Raskind, M. A., & Peskind, E. R. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181ab8c61 · Cited by 208 · see citing works
Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer’s disease
Liu, Y., Yoo, M.-J., Savonenko, A., Stirling, W., Price, D. L., Borchelt, D. R., Mamounas, L., Lyons, W. E., Blue, M. E., & Lee, M. K. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.4218-08.2008 · Cited by 206 · see citing works
Noradrenaline deficiency in brain increases β-amyloid plaque burden in an animal model of Alzheimer's disease
Kalinin, S., Gavrilyuk, V., Polak, P. E., Vasser, R., Zhao, J. J., Heneka, M. T., & Feinstein, D. L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.003 · Cited by 202 · see citing works
Self-citation
Functional Consequences of Locus Coeruleus Degeneration in Alzheimers Disease
Weinshenker, D. (2008) · Current Alzheimer Research · doi:10.2174/156720508784533286 · Cited by 180 · see citing works
Monoamine neurons in aging and Alzheimer's disease
Palmer, A. M., & DeKosky, S. T. (1993) · Journal of Neural Transmission · doi:10.1007/bf01245229 · Cited by 178 · see citing works
Functional Evidence that BDNF Is an Anterograde Neuronal Trophic Factor in the CNS
Fawcett, J. P., Bamji, S. X., Causing, C. G., Aloyz, R. S., Ase, A. R., Reader, T. A., McLean, J. H., & Miller, F. D. (1998) · Journal of Neuroscience · doi:10.1523/jneurosci.18-08-02808.1998 · Cited by 173 · see citing works
Interactions between APP secretases and inflammatory mediators
Sastre, M., Walter, J., & Gentleman, S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-25 · Cited by 172 · see citing works
NEURONAL DEGENERATION IN LOCUS CERULEUS AND CORTICAL CORRELATES OF ALZHEIMER DISEASE
Bondareff, W., Mountjoy, C. Q., Roth, M., Rossor, M. N., Iversen, L. L., Reynolds, G. P., & Hauser, D. L. (1987) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-198701040-00005 · Cited by 166 · cited 2× · see citing works
“, 1992; Mann, 1983; Palmer and DeKosky, 1993; Weinshenker, 2008), and are correlated with plaque and tangle numbers (Bondareff et al., 1987) and duration of illness (Zarow et al.”
Background
Restoration of Norepinephrine-Modulated Contextual Memory in a Mouse Model of Down Syndrome
Salehi, A., Faizi, M., Colas, D., Valletta, J. S., Laguna, J., Takimoto‐Kimura, R., Kleschevnikov, A. M., Wagner, S. L., Aisen, P. S. S., Shamloo, M., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000258 · Cited by 159 · see citing works
Neurotrophic factor therapy for Parkinson’s disease
Rangasamy, S. B., Soderstrom, K. E., Bakay, R. A. E., & Kordower, J. H. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84013-0 · Cited by 155 · see citing works
Noradrenaline activation of neurotrophic pathways protects against neuronal amyloid toxicity
Counts, S., & Mufson, E. J. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06622.x · Cited by 154 · see citing works
Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer’s disease transgenic mice
Kimura, R., Devi, L., & Ohno, M. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06608.x · Cited by 139 · see citing works
The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system
Mann, D. M. A. (1983) · Mechanisms of Ageing and Development · doi:10.1016/0047-6374(83)90100-8 · Cited by 135 · see citing works
Propranolol for Disruptive Behaviors in Nursing Home Residents With Probable or Possible Alzheimer Disease
Peskind, E. R., Tsuang, D. W., Bonner, L. T., Pascualy, M., Riekse, R. G., Snowden, M. B., Thomas, R. G., & Raskind, M. A. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000155067.16313.5e · Cited by 133 · see citing works
Induced LC degeneration in APP/PS1 transgenic mice accelerates early cerebral amyloidosis and cognitive deficits
Jardanhazi‐Kurutz, D., Kummer, M. P., Terwel, D., Vogel, K., Dyrks, T., Thiele, A., & Heneka, M. T. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.02.001 · Cited by 133 · see citing works
Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis
Hoogendijk, W. J. G., Pool, C. W., Troost, D., van Zwieten, E. J., & Swaab, D. F. (1995) · Brain · doi:10.1093/brain/118.1.131 · Cited by 132 · see citing works
Isoproterenol regulates tumour necrosis factor, interleukin‐10, interleukin‐6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia
Szabó, C., Haskó, G., Zingarelli, B., Nemeth, Z. H., Salzman, A. L., Kvetan, V., Pastores, S. M., & Vizi, E. S. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00137.x · Cited by 132 · see citing works
Norepinephrine Suppresses Inducible Nitric Oxide Synthase Activity in Rat Astroglial Cultures
Feinstein, D. L., Galea, E., & Reis, D. J. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb13425.x · Cited by 129 · see citing works
Non-Steroidal Anti-Inflammatory Drugs and Alzheimers Disease: The Epidemiological Evidence
Szekely, C. A., & Zandi, P. P. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791012026 · Cited by 114 · see citing works
Changes in adrenoreceptors in the prefrontal cortex of subjects with dementia: Evidence of compensatory changes
Szot, P., White, S. S., Greenup, J. L., Leverenz, J. B., Peskind, E. R., & Raskind, M. A. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2007.01.031 · Cited by 107 · see citing works
Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β‐induced neurite atrophy
Urano, T., & Tohda, C. (2010) · Phytotherapy Research · doi:10.1002/ptr.3183 · Cited by 101 · see citing works
L‐Dihydroxyphenylserine (L‐DOPS): A Norepinephrine Prodrug
Goldstein, D. S. (2006) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2006.00189.x · Cited by 94 · see citing works
Mechanisms of Action of Non-Steroidal Anti-Inflammatory Drugs for the Prevention of Alzheimers Disease
Cole, G. M., & Frautschy, S. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791011991 · Cited by 84 · see citing works
Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease
Chan‐Palay, V. (1991) · Progress in brain research · doi:10.1016/s0079-6123(08)63839-x · Cited by 84 · see citing works
Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice
Guérin, D., Sacquet, J., Mandairon, N., Jourdan, F., & Didier, A. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.05.020 · Cited by 82 · see citing works
Neuroprotective actions of noradrenaline: effects on glutathione synthesis and activation of peroxisome proliferator activated receptor delta
Madrigal, J. L. M., Kalinin, S., Richardson, J. C., & Feinstein, D. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04888.x · Cited by 77 · see citing works
Self-citation
The Phenotypic Differentiation of Locus Ceruleus Noradrenergic Neurons Mediated by Brain-Derived Neurotrophic Factor Is Enhanced by Corticotropin Releasing Factor through the Activation of a cAMP-Dependent Signaling Pathway
Traver, S., Marien, M. R., Martin, E., Hirsch, É. C., & Michel, P. P. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.022715 · Cited by 71 · see citing works
Increasing CNS Noradrenaline Reduces EAE Severity
Simonini, M. V., Polak, P. E., Sharp, A. J., McGuire, S. O., Galea, E., & Feinstein, D. L. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9182-2 · Cited by 69 · see citing works
Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice
O’Neil, J. N., Mouton, P. R., Tizabi, Y., Ottinger, M. A., Lei, D.-L., Ingram, D. K., & Manaye, K. F. (2007) · Journal of Chemical Neuroanatomy · doi:10.1016/j.jchemneu.2007.05.008 · Cited by 67 · see citing works
Noradrenaline reuptake inhibitors inhibit expression of chemokines IP-10 and RANTES and cell adhesion molecules VCAM-1 and ICAM-1 in the CNS following a systemic inflammatory challenge
O’Sullivan, J. B., Ryan, K. M., Harkin, A., & Connor, T. J. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.12.007 · Cited by 66 · see citing works
Atomoxetine Augmentation of Cholinesterase Inhibitor Therapy in Patients With Alzheimer Disease: 6-Month, Randomized, Double-Blind, Placebo-Controlled, Parallel-Trial Study
Mohs, R. C., Shiovitz, T. M., Tariot, P. N., Porsteinsson, A. P., Baker, K. D., & Feldman, P. D. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181aad585 · Cited by 59 · see citing works
Innate Differences in the Expression of Brain‐Derived Neurotrophic Factor in the Regions Within the Extended Amygdala Between Alcohol Preferring and Nonpreferring Rats
Prakash, A., Zhang, H., & Pandey, S. C. (2008) · Alcoholism Clinical and Experimental Research · doi:10.1111/j.1530-0277.2008.00650.x · Cited by 52 · see citing works
The PDAPP mouse model of Alzheimer's disease: Locus coeruleus neuronal shrinkage
German, D. C., Nelson, O. L., Liang, F., Liang, C., & Games, D. (2005) · The Journal of Comparative Neurology · doi:10.1002/cne.20744 · Cited by 50 · see citing works
Late onset loss of hippocampal 5-HT and NE is accompanied by increases in BDNF protein expression in mice co-expressing mutant APP and PS1
Szapacs, M. E., Numis, A. L., & Andrews, A. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.010 · Cited by 49 · see citing works
Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons
Holm, P. C., Rodríguez, F. J., Kresse, A. E., Canals, J. M., Silos‐Santiago, I., & Arenas, E. (2003) · Development · doi:10.1242/dev.00565 · Cited by 45 · see citing works
Chronic treatment with the α2-adrenoceptor antagonist fluparoxan prevents age-related deficits in spatial working memory in APP×PS1 transgenic mice without altering β-amyloid plaque load or astrocytosis
Scullion, G. A., Kendall, D. A., Marsden, C. A., Sunter, D., & Pardon, M. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.09.002 · Cited by 44 · see citing works
Differential regulation of GDNF, neurturin, and their receptors in primary cultures of rat glial cells
Remy, S., Naveilhan, P., Brachet, P., & Neveu, I. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.1072 · Cited by 42 · see citing works
Effects of Noradrenaline on Neuronal NOS2 Expression and Viability
Madrigal, J. L. M., Russo, C. D., Gavrilyuk, V., & Feinstein, D. L. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.885 · Cited by 36 · see citing works
Second Messenger Systems in the Regulation of Cytokines and Adhesion Molecules in the Central Nervous System
Benveniste, E. N., Huneycutt, B. S., Shrikant, P., & Ballestas, M. E. (1995) · Brain Behavior and Immunity · doi:10.1006/brbi.1995.1029 · Cited by 35 · see citing works
Beta-Amyloid-Dependent Expression of NOS2in Neurons: Prevention by an α2-Adrenergic Antagonist
Kalinin, S., Polak, P. E., Madrigal, J. L. M., Gavrilyuk, V., Sharp, A. J., Chauhan, N. B., Marien, M. R., Colpaert, F. C., & Feinstein, D. L. (2006) · Antioxidants and Redox Signaling · doi:10.1089/ars.2006.8.873 · Cited by 32 · see citing works
Self-citation
Repeated administration of the noradrenergic neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) modulates neuroinflammation and amyloid plaque load in mice bearing amyloid precursor protein and presenilin-1 mutant transgenes
Pugh, P. L., Vidgeon-Hart, M., Ashmeade, T. E., Culbert, A. A., Seymour, Z. M., Perren, M. J., Joyce, F., Bate, S. T., Babin, A. L., Virley, D. J., et al. (2007) · Journal of Neuroinflammation · doi:10.1186/1742-2094-4-8 · Cited by 28 · see citing works

Flagged first, then by citations

Research works printed but not linked: 1

Holm PC Rodriguez FJ Kresse A Canals JM Silos-Santiago I Arenas E 2003b Crucial role of TrkB ligands in the survival and phenotypic differentiation of developing locus coeruleus noradrenergic neurons Development 130 3535 3545 12810600

Sorted by citations

Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · see citing works
Self-citation
Microglia in Neuroinflammation and Neurodegeneration: From Understanding to Therapy
Muzio, L., Viotti, A., & Martino, G. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.742065 · Cited by 581 · see citing works
The Locus Coeruleus: Essential for Maintaining Cognitive Function and the Aging Brain
Mather, M., & Harley, C. W. (2016) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2016.01.001 · Cited by 485 · see citing works
Olfaction in Parkinson's disease and related disorders
Doty, R. L. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.026 · Cited by 431 · see citing works
Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases
Betts, M. J., Kirilina, E. P., Otaduy, M. C. G., Ivanov, D., Acosta‐Cabronero, J., Callaghan, M. F., Lambert, C., Cárdenas‐Blanco, A., Pine, K., Passamonti, L., et al. (2019) · Brain · doi:10.1093/brain/awz193 · Cited by 349 · see citing works
Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease
Weinshenker, D. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.01.010 · Cited by 323 · see citing works
Monoaminergic neuropathology in Alzheimer’s disease
Šimić, G., Leko, M. B., Wray, S., Harrington, C. R., Delalle, I., Milošević, N. J., Bažadona, D., Buée, L., de Silva, R., Giovanni, G. D., et al. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.001 · Cited by 289 · see citing works
Locus coeruleus cellular and molecular pathology during the progression of Alzheimer’s disease
Kelly, S. C., He, B., Perez, S. E., Ginsberg, S. D., Mufson, E. J., & Counts, S. E. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0411-2 · Cited by 286 · see citing works
Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer’s disease
Rorabaugh, J. M., Chalermpalanupap, T., Botz-Zapp, C. A., Fu, V. M., Lembeck, N. A., Cohen, R. M., & Weinshenker, D. (2017) · Brain · doi:10.1093/brain/awx232 · Cited by 227 · see citing works
Genetic mouse models of brain ageing and Alzheimer's disease
Bilkei‐Gorzó, A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.009 · Cited by 244 · see citing works
Brain plasticity-based therapeutics
Merzenich, M. M., Vleet, T. V., & Nahum, M. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00385 · Cited by 242 · see citing works
Ascending monoaminergic systems alterations in Alzheimer's disease. Translating basic science into clinical care
Trillo, L., Das, D., Hsieh, W., Medina, B., Moghadam, S., Lin, B., Dang, V., Sanchez, M. M., Miguel, Z. D., Ashford, J. W., et al. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.05.008 · Cited by 224 · see citing works
Noradrenergic dysfunction in Alzheimer's disease
Gannon, M. A., Che, P., Chen, Y., Jiao, K., Roberson, E. D., & Wang, Q. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00220 · Cited by 211 · see citing works
Causes, consequences, and cures for neuroinflammation mediated via the locus coeruleus: noradrenergic signaling system
Feinstein, D. L., Kalinin, S., & Braun, D. J. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13447 · Cited by 178 · see citing works
Self-citation
In vivo MRI assessment of the human locus coeruleus along its rostrocaudal extent in young and older adults
Betts, M. J., Cárdenas‐Blanco, A., Kanowski, M., Jessen, F., & Düzel, E. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.09.042 · Cited by 165 · see citing works
Behavioural and psychological symptoms of dementia in mouse models of Alzheimer’s disease-related pathology
Kosel, F., Pelley, J. M. S., & Franklin, T. B. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.02.012 · Cited by 162 · see citing works
The mechanistic link between selective vulnerability of the locus coeruleus and neurodegeneration in Alzheimer’s disease
Matchett, B. J., Grinberg, L. T., Theofilas, P., & Murray, M. E. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02248-1 · Cited by 162 · see citing works
Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease
Chalermpalanupap, T., Kinkead, B. L., Hu, W. T., Kummer, M. P., Hammerschmidt, T., Heneka, M. T., Weinshenker, D., & Levey, A. I. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt175 · Cited by 145 · see citing works
Orthostatic hypotension and cognitive impairment in Parkinson's disease: Causation or association?
McDonald, C., Newton, J. L., & Burn, D. J. (2016) · Movement Disorders · doi:10.1002/mds.26632 · Cited by 145 · see citing works
Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease
Bhattacharya, S., Haertel, C., Maelicke, A., & Montag, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089454 · Cited by 142 · see citing works
“Furthermore, a reduced plaque burden has been shown to be accompanied by a reduced glial activation [6,60].”
Norepinephrine Inhibits Alzheimer’s Amyloid-β Peptide Aggregation and Destabilizes Amyloid-β Protofibrils: A Molecular Dynamics Simulation Study
Zou, Y. F., Qian, Z., Chen, Y., Qian, H., Wei, G., & Zhang, Q. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00537 · Cited by 120 · see citing works
The Locus Coeruleus in Aging and Alzheimer’s Disease: A Postmortem and Brain Imaging Review
Beardmore, R., Hou, R. H., Darekar, A., Holmes, C., & Boche, D. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210191 · Cited by 120 · see citing works
Onset of hippocampus-dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer’s disease
Girard, S. D., Jacquet, M., Baranger, K., Migliorati, M., Escoffier, G., Bernard, A., Khrestchatisky, M., Féron, F., Rivera, S., Roman, F. S., et al. (2014) · Hippocampus · doi:10.1002/hipo.22267 · Cited by 119 · see citing works
Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer’s disease model mice
Woodling, N. S., Colas, D., Wang, Q., Minhas, P. S., Panchal, M., Liang, X., Mhatre, S. D., Brown, H. D., Ko, N., Zagol-Ikapitte, I. A., et al. (2016) · Brain · doi:10.1093/brain/aww117 · Cited by 108 · see citing works
Evidence for early cognitive impairment related to frontal cortex in the 5xFAD mouse model of Alzheimer’s disease.
Girard, S. D., Baranger, K., Gauthier, C., Jacquet, M., Bernard, A., Escoffier, G., Marchetti, E., Khrestchatisky, M., Rivera, S., & Roman, F. S. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120982 · Cited by 107 · see citing works
Alzheimer’s disease pathology: pathways between central norepinephrine activity, memory, and neuropsychiatric symptoms
Jacobs, H. I. L., Riphagen, J. M., Ramakers, I. H. G. B., & Verhey, F. R. J. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0437-x · Cited by 103 · see citing works
A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment
Levey, A. I., Qiu, D., Zhao, L., Hu, W. T., Duong, D. M., Higginbotham, L. A., Dammer, E. B., Seyfried, N. T., Wingo, T. S., Hales, C. M., et al. (2021) · Brain · doi:10.1093/brain/awab452 · Cited by 101 · see citing works
EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimerŉs disease
Tai, L. M., Balu, D., Avila-Munoz, E., Abdullah, L., Thomas, R., Collins, N., Valencia-Olvera, A. C., & LaDu, M. J. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r076315 · Cited by 93 · see citing works
Dopamine beta‐hydroxylase and its genetic variants in human health and disease
Gonzalez‐Lopez, E., & Vrana, K. E. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14893 · Cited by 91 · see citing works
Jujuboside A, a neuroprotective agent from semen Ziziphi Spinosae ameliorates behavioral disorders of the dementia mouse model induced by Aβ1–42
Liu, Z., Zhao, X. D., Liu, B., Liu, A., Li, H., Mao, X., Wu, B. M., Kai-shun, B., & Jia, Y. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.05.041 · Cited by 90 · see citing works
Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist
Ardestani, P. M., Evans, A. K., Yi, B., Nguyen, T., Coutellier, L. D., & Shamloo, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.01.010 · Cited by 88 · see citing works
Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer’s Disease: A Review
Vargas‐Caballero, M., Warming, H., Walker, R., Holmes, C., Cruickshank, G. S., & Patel, B. (2022) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2022.866434 · Cited by 87 · see citing works
Pharmacogenomics of Alzheimer’s Disease: Novel Therapeutic Strategies for Drug Development
Cacabelos, R., Cacabelos, P., Torrellas, C., Tellado, I., & Carril, J. C. (2014) · Methods in molecular biology · doi:10.1007/978-1-4939-0956-8_13 · Cited by 85 · see citing works
Anti-amnesic effect of pseudoginsenoside-F11 in two mouse models of Alzheimer's disease
Wang, C., Liu, M.-Y., Wang, F., Wei, M., Wang, S., Wu, C., & Yang, J. (2013) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.03.010 · Cited by 79 · see citing works
Reduced Tissue Levels of Noradrenaline Are Associated with Behavioral Phenotypes of the TgCRND8 Mouse Model of Alzheimer's Disease
Francis, B. M., Yang, J., Hajderi, E., Brown, M. E., Michalski, B., McLaurin, J., Fahnestock, M. L., & Mount, H. T. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.40 · Cited by 75 · see citing works
Comparison of memory, affective behavior, and neuropathology in APPNLGF knock-in mice to 5xFAD and APP/PS1 mice
Locci, A., Orellana, H., Rodríguez, G., Gottliebson, M., McClarty, B. M., Dominguez, S., Keszycki, R. M., & Dong, H. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113192 · Cited by 68 · see citing works
Roles of tau pathology in the locus coeruleus (LC) in age-associated pathophysiology and Alzheimer’s disease pathogenesis: Potential strategies to protect the LC against aging
Satoh, A., & Iijima, K. (2017) · Brain Research · doi:10.1016/j.brainres.2017.12.027 · Cited by 68 · see citing works
Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases
Giovanni, G. D., Štrac, D. Š., Solé, M., Unzeta, M., Tipton, K. F., Mück‐Šeler, D., Bolea, I., Corte, L., Perković, M. N., Pivac, N., et al. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00541 · Cited by 71 · see citing works
Prazosin, an α1-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease
Katsouri, L., Vizcaychipi, M. P., McArthur, S., Harrison, I. F., Suárez‐Calvet, M., Lleó, A., Lloyd, D. G., Ma, D., & Sastre, M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.09.010 · Cited by 66 · see citing works
Norepinephrine Protects against Amyloid-β Toxicity via TrkB
Liu, X., Ye, K., & Weinshenker, D. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-141062 · Cited by 60 · see citing works
Locus coeruleus in the pathogenesis of Alzheimer's disease: A systematic review
Chen, Y., Chen, T., & Hou, R. H. (2022) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.12257 · Cited by 57 · see citing works
Neural Consequences of Chronic Short Sleep: Reversible or Lasting?
Zhao, Z., Zhao, X., & Veasey, S. C. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00235 · Cited by 58 · see citing works
Noradrenergic Regulation of Glial Activation: Molecular Mechanisms and Therapeutic Implications
Braun, D. J., Madrigal, J. L. M., & Feinstein, D. L. (2014) · Current Neuropharmacology · doi:10.2174/1570159x12666140828220938 · Cited by 56 · see citing works
Report and Research Agenda of the American Geriatrics Society and National Institute on Aging Bedside‐to‐Bench Conference on Sleep, Circadian Rhythms, and Aging: New Avenues for Improving Brain Health, Physical Health, and Functioning
Fung, C. H., Vitiello, M. V., Alessi, C., & Kuchel, G. A. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14493 · Cited by 52 · see citing works
Noradrenergic Dysfunction in Alzheimer's and Parkinson's Diseases—An Overview of Imaging Studies
Peterson, A. C., & Li, C. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00127 · Cited by 54 · see citing works
Neuroprotective, Neurogenic, and Amyloid Beta Reducing Effect of a Novel Alpha 2-Adrenoblocker, Mesedin, on Astroglia and Neuronal Progenitors upon Hypoxia and Glutamate Exposure
Melkonyan, M. M., Hunanyan, L. S., Lourhmati, A., Layer, N., Beer‐Hammer, S., Yenkoyan, K. B., Schwab, M. G., & Danielyan, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms19010009 · Cited by 49 · see citing works
Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer’s disease mice
Torika, N., Asraf, K., Cohen, H., & Fleisher‐Berkovich, S. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.04.001 · Cited by 47 · see citing works
Motor coordination and synaptic plasticity deficits are associated with increased cerebellar activity of NADPH oxidase, CAMKII, and PKC at preplaque stage in the TgCRND8 mouse model of Alzheimer's disease.
Russo, R., Cattaneo, F., Lippiello, P., Cristiano, C., Zurlo, F., Castaldo, M., Irace, C., Borsello, T., Santamaria, R., Ammendola, R., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.02.025 · Cited by 47 · see citing works
Noradrenaline in Alzheimer’s Disease: A New Potential Therapeutic Target
Gutiérrez, I. L., Russo, C. D., Novellino, F., Caso, J. R., García‐Bueno, B., Leza, J. C., & Madrigal, J. L. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116143 · Cited by 49 · see citing works
Catecholamines in Alzheimer's Disease: A Systematic Review and Meta-Analysis
Pan, X., Kaminga, A. C., Jia, P., Wen, S. W., Acheampong, K., & Liu, A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00184 · Cited by 44 · see citing works
Locus Coeruleus Magnetic Resonance Imaging in Neurological Diseases
Galgani, A., Lombardo, F. P., Latta, D. D., Martini, N., Bonuccelli, U., Fornai, F., & Giorgi, F. S. (2020) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-020-01087-7 · Cited by 43 · see citing works
Microglial CX3CR1 production increases in Alzheimer's disease and is regulated by noradrenaline
González-Prieto, M., Gutiérrez, I. L., García-Bueno, B., Caso, J., Leza, J., Ortega-Hernández, A., Gómez-Garre, D., & Madrigal, J. (2020) · Glia · doi:10.1002/glia.23885 · Cited by 37 · see citing works
Locus Coeruleus Degeneration Induces Forebrain Vascular Pathology in a Transgenic Rat Model of Alzheimer’s Disease
Kelly, S. C., McKay, E. C., Beck, J. S., Collier, T. J., Dorrance, A. M., & Counts, S. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190090 · Cited by 43 · see citing works
Drug pipeline in neurodegeneration based on transgenic mice models of Alzheimer's disease
Li, C., Ebrahimi, A., & Schluesener, H. J. (2012) · Ageing Research Reviews · doi:10.1016/j.arr.2012.09.002 · Cited by 39 · see citing works
Preventing neurodegeneration by adrenergic astroglial excitation
Zorec, R., Parpura, V., & Verkhratsky, A. (2018) · FEBS Journal · doi:10.1111/febs.14456 · Cited by 39 · see citing works
Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription and activity: Implications for cellular Aβ metabolism
Leal, M. C., Surace, E., Holgado, M., Ferrari, C., Tarelli, R., Pitossi, F., Wisniewski, T., Castaño, E., & Morelli, L. (2011) · Biochimica et Biophysica Acta · doi:10.1016/j.bbamcr.2011.09.014 · Cited by 41 · see citing works
The locus coeruleus neuroprotective drug vindeburnol normalizes behavior in the 5xFAD transgenic mouse model of Alzheimer’s disease
Braun, D. J., & Feinstein, D. L. (2017) · Brain Research · doi:10.1016/j.brainres.2017.12.028 · Cited by 36 · see citing works
The vincamine derivative vindeburnol provides benefit in a mouse model of multiple sclerosis: effects on the Locus coeruleus
Polak, P. E., Kalinin, S., Braun, D. J., Sharp, A. J., Lin, S. X., & Feinstein, D. L. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2012.07673.x · Cited by 35 · see citing works
Self-citation
Reboxetine Treatment Reduces Neuroinflammation and Neurodegeneration in the 5xFAD Mouse Model of Alzheimer’s Disease: Role of CCL2
Gutiérrez, I. L., González‐Prieto, M., Caso, J. R., García‐Bueno, B., Leza, J. C., & Madrigal, J. L. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-01695-6 · Cited by 35 · see citing works
Dual effects of noradrenaline on astroglial production of chemokines and pro-inflammatory mediators
Hinojosa, A. E., Caso, J. R., García‐Bueno, B., Leza, J. C., & Madrigal, J. L. M. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-81 · Cited by 34 · see citing works
Development of amyloid burden in African Green monkeys
Kalinin, S., Willard, S. L., Shively, C. A., Kaplan, J. R., Register, T. C., Jorgensen, M. J., Polak, P. E., Rubinstein, I., & Feinstein, D. L. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.023 · Cited by 32 · see citing works
Self-citation
Aβ pathology downregulates brain mGluR5 density in a mouse model of Alzheimer
Lee, M., Lee, H., Park, I. S., Park, J. A., Kwon, Y., Ryu, Y. H., Kim, C. H., Kang, J. H., Hyun, I. Y., Lee, K. C., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.02.003 · Cited by 30 · see citing works
Conditional Depletion of Hippocampal Brain-Derived Neurotrophic Factor Exacerbates Neuropathology in a Mouse Model of Alzheimer’s Disease
Braun, D. J., Kalinin, S., & Feinstein, D. L. (2017) · ASN NEURO · doi:10.1177/1759091417696161 · Cited by 28 · see citing works
Self-citation
Widespread Reduced Density of Noradrenergic Locus Coeruleus Axons in the App Knock-In Mouse Model of Amyloid-β Amyloidosis
Sakakibara, Y., Hirota, Y., Ibaraki, K., Takei, K., Chikamatsu, S., Tsubokawa, Y., Saito, T., Saido, T. C., Sekiya, M., & Iijima, K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210385 · Cited by 26 · see citing works
D5 receptor agonist 027075 promotes cognitive function recovery and neurogenesis in a Aβ1-42-induced mouse model
Shen, L., Yan, M., & He, L. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.008 · Cited by 26 · see citing works
Effects of methylphenidate on the behavior of male 5xFAD mice
Schneider, F. W., Baldauf, K., Wetzel, W., & Reymann, K. G. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.11.006 · Cited by 25 · see citing works
Catecholamine-Based Treatment in AD Patients: Expectations and Delusions
Stefani, A., Olivola, E., Liguori, C., Hainsworth, A. H., Saviozzi, V., Angileri, G., D’Angelo, V., Galati, S., & Pierantozzi, M. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00067 · Cited by 24 · see citing works
Noradrenaline induces CX3CL1 production and release by neurons
Madrigal, J. L. M., Caso, J. R., García‐Bueno, B., Gutiérrez, I. L., & Leza, J. C. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.001 · Cited by 22 · see citing works
Differential effects on glial activation by a direct versus an indirect thrombin inhibitor
Marangoni, N., Braun, D. J., Situ, A., Moyano, A. L., Kalinin, S., Polak, P. E., Givogri, M. I., & Feinstein, D. L. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.05.018 · Cited by 22 · see citing works
Self-citation
Epigenetic dysregulation of brainstem nuclei in the pathogenesis of Alzheimer’s disease: looking in the correct place at the right time?
Iatrou, A., Kenis, G., Rutten, B. P. F., Lunnon, K., & van den Hove, D. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2361-4 · Cited by 21 · see citing works
2-pentadecyl-2-oxazoline prevents cognitive and social behaviour impairments in the Amyloid β-induced Alzheimer-like mice model: Bring the α2 adrenergic receptor back into play
Infantino, R., Boccella, S., Scuteri, D., Perrone, M., Ricciardi, F., Vitale, R. M., Bonsale, R., Parente, A., Allocca, I., Virtuoso, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113844 · Cited by 19 · see citing works
Autophagy status as a gateway for stress-induced catecholamine interplay in neurodegeneration
Fornai, F., & Puglisi‐Allegra, S. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.01.015 · Cited by 20 · see citing works
Noradrenergic signaling controls Alzheimer's disease pathology via activation of microglial β2 adrenergic receptors
Le, L., Feidler, A. M., Rodrı́guez, L., Cealie, M. Y., Plunk, E. C., Li, H., Kara-Pabani, K., Lamantia, C. E., O’Banion, M. K., & Majewska, A. K. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.04.022 · Cited by 18 · see citing works
Dysfunction of norepinephrine and its metabolites in Alzheimer's dementia – A review with meta-analysis
Moreira, I. P., Henriques, T. S., Vieira‐Coelho, M. A., & Guimarães, J. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101784 · Cited by 18 · see citing works
Brainstem noradrenergic neurons: Identifying a hub at the intersection of cognition, motility, and skeletal muscle regulation
Delbono, O., Wang, Z., & Messi, M. L. (2022) · Acta Physiologica · doi:10.1111/apha.13887 · Cited by 17 · see citing works
L‐Threo‐Dihydroxyphenylserine corrects neurochemical abnormalities in a menkes disease mouse model
Donsante, A., Sullivan, P., Goldstein, D. S., Brinster, L., & Kaler, S. G. (2012) · Annals of Neurology · doi:10.1002/ana.23787 · Cited by 16 · see citing works
Alzheimer's disease-like pathology-triggered oxidative stress, alterations in monoamines levels, and structural damage of locus coeruleus neurons are partially recovered by a mix of proteoglycans of embryonic genesis
Aghajanov, M. I., Chavushyan, V. A., Matinyan, S., Danielyan, M., & Yenkoyan, K. B. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.104531 · Cited by 16 · see citing works
Cognitive Impairment in Alzheimer’s and Metabolic Diseases: A Catecholaminergic Hypothesis
Guzmán-Ramos, K. R., Osorio‐Gómez, D., & Bermúdez‐Rattoni, F. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.031 · Cited by 15 · see citing works
Light‐exercise‐induced dopaminergic and noradrenergic stimulation in the dorsal hippocampus: Using a rat physiological exercise model
Hiraga, T., Hata, T., Soya, S., Shimoda, R., Takahashi, K., Soya, M., Inoue, K., Johansen, J. P., Okamoto, M., & Soya, H. (2024) · The FASEB Journal · doi:10.1096/fj.202400418rrr · Cited by 13 · see citing works
Transcription Factors Phox2a/2b Upregulate Expression of Noradrenergic and Dopaminergic Phenotypes in Aged Rat Brains
Fan, Y., Zeng, F., Brown, R. W., Price, J. B., Jones, T. C., & Zhu, M. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00250-9 · Cited by 13 · see citing works
Noradrenergic therapies in neurodegenerative disease: from symptomatic to disease modifying therapy?
Durcan, R., O’Callaghan, C., & Rowe, J. B. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf310 · Cited by 14 · see citing works
Localization of endogenous amyloid-β to the coeruleo-cortical pathway: consequences of noradrenergic depletion
Ross, J. A., Reyes, B. A. S., THOMAS, S. A., & Bockstaele, E. J. V. (2017) · Brain Structure and Function · doi:10.1007/s00429-017-1489-9 · Cited by 12 · see citing works
Assessing disease-modifying effects of norepinephrine in Down syndrome and Alzheimer’s disease
Ponnusamy, R., McNerney, M. W., Moghadam, S., & Salehi, A. (2017) · Brain Research · doi:10.1016/j.brainres.2017.09.035 · Cited by 11 · see citing works
Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer’s disease
Shade, R. D., Ross, J. A., & Bockstaele, E. J. V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.949361 · Cited by 9 · see citing works
Partial microglial depletion and repopulation exert subtle but differential effects on amyloid pathology at different disease stages
Le, L., O’Banion, M. K., & Majewska, A. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-81910-0 · Cited by 8 · see citing works
Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease
Matt, R. A., Martin, R. S., Evans, A. K., Gever, J. R., Vargas, G. A., Shamloo, M., & Ford, A. P. D. W. (2023) · Handbook of experimental pharmacology · doi:10.1007/164_2023_677 · Cited by 10 · see citing works
Animal Models of Alzheimer’s Disease
Amram, S., & Frenkel, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803690-7.00003-x · Cited by 8 · see citing works
Early β adrenoceptor dependent time window for fear memory persistence in APPswe/PS1dE9 mice
Karunakaran, S. (2021) · Scientific Reports · doi:10.1038/s41598-020-79487-5 · Cited by 7 · see citing works
The impacts of sex and the 5xFAD model of Alzheimer’s disease on the sleep and spatial learning responses to feeding time
Campbell, K. J., Jiang, P., Olker, C. J., Lin, X., Kim, S. Y., Lee, C., Song, E. J., Turek, F. W., & Vitaterna, M. H. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1430989 · Cited by 6 · see citing works
Progress in novel cognitive enhancers for cognitive aging and Alzheimer’s disease
Shineman, D. W., Carman, A. J., Dacks, P. A., Lane, R. F., & Fillit, H. M. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt209 · Cited by 6 · see citing works
Repeated exposure to novelty promotes resilience against the amyloid-beta effect through dopaminergic stimulation
Velázquez-Delgado, C., Hernández-Ortiz, E., Landa‐Navarro, L., Rodríguez, M. T., Moreno‐Castilla, P., & Bermúdez‐Rattoni, F. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06650-5 · Cited by 5 · see citing works
Characterization of locus coeruleus neuronal properties with aging in two mouse models of tauopathy
Potts, Y., Daykin, H. J., Bossche, M. J. A. V. D., McDougall, S. J., & Jacobson, L. H. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251393515 · Cited by 4 · see citing works
Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders
Perez‐Lloret, S., Rey, M. V., Traon, A. P., & Rascol, O. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.901167 · Cited by 4 · see citing works
Pathogenic tau in the mouse locus coeruleus produces noradrenergic hyperactivity and neuropsychiatric phenotypes reminiscent of early Alzheimer’s disease
Korukonda, A., Blankenship, H. E., Kam, K., Kour, D., Espinosa‐García, C., Jang, W. E., Srivastava, U., Mulvey, B., Tish, M. M., Witztum, R., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03852-5 · Cited by 3 · see citing works
The Use of DREADDs for Dissecting the Contribution of Cellular and Neural Circuit Mechanisms in Models of Neurodegenerative Disease
Sharma, P., & Pienaar, I. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-804078-2.00024-6 · Cited by 3 · see citing works
Pharmacologically Manipulating Learning and Memory
Fortress, A. M., & Frick, K. M. (2014) · Neuromethods · doi:10.1007/978-1-4939-2159-1_7 · Cited by 3 · see citing works
Sleep Loss and Neuronal Stress
Naidoo, N. N. (2019) · Springer eBooks · doi:10.1007/978-981-13-2814-5_3 · Cited by 3 · see citing works
Photostimulation of locus coeruleus CA1 catecholaminergic terminals reversed Spatial memory impairment in an alzheimer’s disease mouse model
Gálvez-Márquez, D. K., Urrego-Morales, O., Rodríguez-Durán, L. F., & Bermúdez‐Rattoni, F. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06885-w · Cited by 3 · see citing works
Alzheimer model 5xfad mice and applications to dementia
Ayabe, T., & Ano, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00052-9 · Cited by 2 · see citing works
Neuroinflammation in Alzheimer's Disease
(2020) · Case Medical Research · doi:10.31525/ct1-nct04274998 · Cited by 2 · see citing works

Selective Loss of Noradrenaline Exacerbates Early Cognitive Dysfunction and Synaptic Deficits in APP/PS1 Mice
Hammerschmidt, T., Kummer, M. P., Terwel, D., Martinez, A., Gorji, A., Pape, H., Rommelfanger, K. S., Schroeder, J. P., Stoll, M., Schultze, J. L., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.06.013 · Cited by 111 · see citing works
Noradrenaline deficiency in brain increases β-amyloid plaque burden in an animal model of Alzheimer's disease
Kalinin, S., Gavrilyuk, V., Polak, P. E., Vasser, R., Zhao, J. J., Heneka, M. T., & Feinstein, D. L. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.003 · Cited by 202 · see citing works
Self-citation
Damage to the Locus Coeruleus in Alzheimer's Disease: Potential Causes and Therapeutic Targets
Braun, D. J. (2016) · Figshare
Reduced Tissue Levels of Noradrenaline Are Associated with Behavioral Phenotypes of the TgCRND8 Mouse Model of Alzheimer's Disease
Francis, B. M., Yang, J., Hajderi, E., Brown, M. E., Michalski, B., McLaurin, J., Fahnestock, M. L., & Mount, H. T. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2012.40 · Cited by 75 · see citing works
Noradreneline deficiency aggrevates learning and memory impairment independent of Aß Levels in APPPS1 mice
Hammerschmidt, T., Kummer, M. P., Gorji, A., Terwel, D., Weinshenker, D., Pape, H., & Heneka, M. T. (2008) · Aktuelle Neurologie · doi:10.1055/s-0028-1086716

Authors: Kalinin, S., Polak, P. E., Lin, S. X., Sakharkar, A. J., Pandey, S. C., & Feinstein, D. L.
Affiliations: University of Illinois Chicago (US)
Corresponding author: Feinstein, Douglas L.
ORCID: Kalinin, Sergey
Polak, Paul E.
Sakharkar, Amul J.
Pandey, Subhash C.
Feinstein, Douglas L.
Venue: Neurobiology of Aging
Publisher: Elsevier BV
Published: 2012-08
Volume: 33
Issue: 8
Pages: 1651-1663
ISSN: 0197-4580 (ISSN-L)
DOI: 10.1016/j.neurobiolaging.2011.04.012
PMC: PMC3646366
OpenAlex: W1991513124
Cited by: 116
References: 59
Citations by year: 2026: 4 · 2025: 6 · 2024: 7 · 2023: 2 · 2022: 9 · 2021: 10 · 2020: 7 · 2019: 9 · 2018: 6 · 2017: 15 · 2016: 11 · 2015: 4 · 2014: 9 · 2013: 9 · 2012: 5
FWCI: 5.67
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Neurobiology of Aging (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: Department of Veterans Affairs
American Alzheimer's Association
NIH (RO1-AA010005)
Topics: Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Alzheimer's disease, norepinephrine, locus coeruleus, 5xFAD mice, amyloid, astrocyte activation, neuroinflammation, learning disabilities, brain-derived neurotrophic factor, neprilysin, insulin-degrading enzyme, neurotrophins, noradrenergic neurons
MeSH terms: Alzheimer Disease, Animals, Antiparkinson Agents, Locus Coeruleus, Male, Mice, Transgenic, Norepinephrine, Droxidopa, Treatment Outcome, Maze Learning, Mice, Adrenergic Neurons

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer’s disease

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks